Open AccessMaintenance treatment with infliximab for ulcerative ileitis after intestinal transplantation: A case report
Author(s) -
Takumi Fujimura,
Yasuaki Yamada,
Tomoshige Umeyama,
Yumi Kudo,
Hiroki Kanamori,
Teizaburo Mori,
Takahiro Shimizu,
Miyako Kato,
Miho Kawaida,
Naoki Hosoe,
Yasushi Hasegawa,
Kentaro Murakami,
Naoki Shimojima,
Masahiro Shinoda,
Hideaki Obara,
Makoto Naganuma,
Yuko Kitagawa,
Ken Hoshino,
Takeshi Kuroda
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i19.5270
Subject(s) - medicine , infliximab , ileitis , ulcerative colitis , gastroenterology , transplantation , crohn's disease , tumor necrosis factor alpha , disease
Evidence has been published on the successful applications of the anti-tumor necrosis factor alpha antibody infliximab, such as induction therapy, salvage treatment for acute cellular rejection, and treatment for chronic ulcerative inflammation, in intestinal transplant recipients. However, the optimal protocol for the effective use of infliximab remains largely undetermined due to scarcity of available clinical data. We report a continuative application of infliximab as maintenance therapy for recurrent chronic ulcerative ileitis in a recipient of isolated intestinal transplantation (ITx).